PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Another study of NAFLD patients who did not have diabetes and were not obese showed that PNPLA3 rs738409 I148M increased the risk for CKD, but TM6SF2 rs58542926 E167K reduced the risk for CKD [25].